NCI have performed a phase IIb trial having 461 participants using Amiket.
The results seems to be excellent? P-value 0,001.
A third part evaluation of the economic outcome from the future Amiket market - in the US alone - seems more than interesting? 400 MUSD per annum. Epicept will seek approval in the EU as well.
We are now waiting for the minutes from the end-of -phase 2-meeting that the representaives have named a "succes" as for the design of the phase III that will start late Q2. After that Epicept will negotiate a SPA for Amikets phase III trial.